Article
Germline assessment for alloHSCT candidates over 50 years: A 'Fast-Track' screening in myeloid neoplasms.
British journal of haematology - 1 Aug 2024
Torres-Esquius Sara, Beas Francisco, Chen-Liang Tzu Hua, Pomares Helena, Santiago Marta, Varela Nicolás Díaz, Liquori Alessandro, Hernandez Francisca, Xicoy Blanca, Hermosín Lourdes, Arnan Montserrat, Tazón-Vega Bárbara, Blanco Adoración, Cervera José, Diez-Campelo María, Lozano María Luisa, Valcárcel David, Bosch Francesc, Montoro Maria Julia, Jerez Andrés
Abstract excerpt
Patients aged 50 or above diagnosed with myeloid neoplasms (MNs) are typically not candidates for germline testing. However, approximately 8% carry pathogenic germline variants. Allogeneic haematopoietic stem cell transplantation (alloHSCT) remains an option for those aged over 50; neglecting germline testing could mask the risk for relative donor cell-derived MN. We propose a germline-augmented somatic panel...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.